HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

US COVID-19 Claim Warnings Continue; Hi-Tech’s Problems Extend To Undeclared Allergens

Executive Summary

Natural Adventure and PYRLess Group are latest firms to learn FDA, FTC continue monitoring the market for claims promoting supplements as COVID-19 treatments. Hi-Tech Pharmaceuticals recalls APS Nutrition Isomorph 28 and iForce Nutrition Mass Gainz due to undeclared allergens.

You may also be interested in...



Has COVID Changed US FDA’s Thinking About OTC Antiseptics?

The public health emergency has shown that the US needs more hand sanitizers on store shelves, not less, right?

Defendant On Criminal Steroid Charges Owns Firm FDA Warns On Stimulant Found In Supplement

Georgia business records indicate the firm FDA warned on 21 May was established in 2017 by Jared Wheat and is registered with an address in an Atlanta suburb also used for Wheat’s Hi-Tech Pharmaceuticals. Wheat is facing 18 criminal charges listed in a 2017 indictment alleging he distributed steroid-spiked supplements and falsified regulatory compliance documents.

As Hi-Tech Argues For DMHA Use, DMAA Seizure Falls In FDA's Criminal Case, Contempt Stands In FTC Complaint

Hi-Tech Pharmaceuticals granted motion in federal court to have $19m in seized DMAA products returned, though the order noted sales of the products are prohibited. As Hi-Tech seeks court order that FDA is wrong about DMAA, an appellate court upholds $40m contempt fine against firm in FTC complaint.

Related Content

Topics

UsernamePublicRestriction

Register

RS151210

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel